<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148108</url>
  </required_header>
  <id_info>
    <org_study_id>TLK286.2030</org_study_id>
    <nct_id>NCT01148108</nct_id>
  </id_info>
  <brief_title>Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma</brief_title>
  <official_title>Phase 2 Study of Canfosfamide HCl for Injection (TelcytaÂ®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in
      relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple
      myeloma. The study will be conducted in two stages with 5-6 patients in each indication in
      Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At 6 weeks of treatment</time_frame>
    <description>Disease will be assessed every 6 weeks using International Working Group Response Criteria for Non-Hodgkins Lymphoma in the mantle cell and diffuse large B cell lymphoma patients and the International Myeloma Working Group Response Criteria for multiple myeloma patients. Patients will continue to be treated and disease assessed until disease progression or unacceptable toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At 12 weeks of treatment</time_frame>
    <description>Disease will be assessed every 6 weeks using International Working Group Response Criteria for Non-Hodgkins Lymphoma in the mantle cell and diffuse large B cell lymphoma patients and the International Myeloma Working Group Response Criteria for multiple myeloma patients. Patients will continue to be treated and disease assessed until disease progression or unacceptable toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At 18 weeks of treatment</time_frame>
    <description>Disease will be assessed every 6 weeks using International Working Group Response Criteria for Non-Hodgkins Lymphoma in the mantle cell and diffuse large B cell lymphoma patients and the International Myeloma Working Group Response Criteria for multiple myeloma patients. Patients will continue to be treated and disease assessed until disease progression or unacceptable toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At 24 weeks of treatment</time_frame>
    <description>Disease will be assessed every 6 weeks using International Working Group Response Criteria for Non-Hodgkins Lymphoma in the mantle cell and diffuse large B cell lymphoma patients and the International Myeloma Working Group Response Criteria for multiple myeloma patients. Patients will continue to be treated and disease assessed until disease progression or unacceptable toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>At 6, 12, 18 &amp; 24 weeks of treatment</time_frame>
    <description>Duration of response will be determined after disease progression is documented in patients who have an objective response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>At 3, 6, 9, &amp; 12 weeks of treatment</time_frame>
    <description>Toxicity will be assessed throughout study using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>B Cell Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Mantle Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory mantle cell lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diffuse Large B Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory diffuse large B cell lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory multiple myeloma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canfosfamide HCl for injection</intervention_name>
    <description>30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks</description>
    <arm_group_label>Mantle Cell Lymphoma</arm_group_label>
    <arm_group_label>Diffuse Large B Cell Lymphoma</arm_group_label>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <other_name>Telcyta</other_name>
    <other_name>TLK286</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsed or refractory disease

          -  histologically or cytologically confirmed disease

          -  characteristic immunophenotypic profiles

          -  measurable disease (for lymphoma patients)

          -  ECOG performance status of 0-2

          -  adequate liver and kidney function

          -  adequate bone marrow reserves

          -  ineligible or unwilling to undergo autologous stem cell transplantation

        Exclusion Criteria:

          -  failure to recover from any major surgery within 4 weeks of study entry

          -  pregnant or lactating women

          -  women of child-bearing potential not using reliable and appropriate contraception

          -  routine prophylactic use of G-CSF required within 2 weeks of study entry

          -  Grade 3 or higher peripheral neuropathy

          -  history of hepatitis B virus or HIV

          -  central nervous system or meningeal involvement by lymphoma or multiple myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Bertino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Non-Hodgkins Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Diffuse Large B Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Telcyta</keyword>
  <keyword>canfosfamide</keyword>
  <keyword>TLK286</keyword>
  <keyword>Prodrug</keyword>
  <keyword>Enzyme activated drug</keyword>
  <keyword>Glutathione Transferase P1-1 activated drug</keyword>
  <keyword>GSTp1-1 activated drug</keyword>
  <keyword>Glutathione Transferase activated drug</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Glutathione analong</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

